亚洲欧美精品在线-亚洲欧美精品中文字幕在线观看-亚洲欧美精品综合在线观看-亚洲欧美精选-亚洲欧美久久-亚洲欧美久久精品

Hello! Welcome to the official website of Betta Pharmaceuticals!
Service Hotline:+86-571-86130357     Add to Favorites | Online Feedback 中文

 


Bevacizumab (MIL60) is the third drug approved for marketing by Betta Pharmaceuticals and the first approved large molecule biologic.

In February 2017, Betta Pharmaceuticals entered into a collaboration with Beijing MAB Works Biotechnology Co., Ltd. for the bevacizumab injection project, and the entrusted manufacturer is Haizheng Biopharmaceutical Co., Ltd., a subsidiary of Zhejiang Borui Biopharmaceutical Co., Ltd.

In December 2019, the phase III clinical study of bevacizumab injection (MIL60) reached the primary study endpoint. It is a randomized, double-blind, multicenter Phase III study comparing the efficacy and safety of MIL60 in combination with paclitaxel and carboplatin to bevacizumab in combination with paclitaxel and carboplatin for the treatment of subjects with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in primary treatment, led by Professor Wang Jie of Cancer Hospital of Chinese Academy of Medical Sciences with the participation of 50 research centers across China.

In June 2020, MIL60 marketing authorization application was accepted by the State Drug Administration.

In September 2021, MIL60 Phase III clinical research results were presented at the 2021 European Society of Medical Oncology (ESMO) Annual Meeting.

In November 2021, bevacizumab injection (MIL60) was officially approved for marketing, and the approved indications are metastatic colorectal cancer and advanced, metastatic or recurrent non-small cell lung cancer.

In December 2021, the results of bevacizumab research were published in EClinicalMedicine, a subjournal of The Lancet. Four new indications (recurrent glioblastoma; hepatocellular carcinoma; epithelial ovarian, fallopian tube or primary peritoneal carcinoma; and cervical cancer) were accepted for application.

In January 2022, the first order of bevacizumab was dispatched and the first prescriptions were written in several locations across China.

In March 2022, several new indications for bevacizumab (indications for the treatment of patients with recurrent glioblastoma, epithelial ovarian, fallopian tube or primary peritoneal cancer, and cervical cancer) were approved.


 

產品介紹.jpg



 


主站蜘蛛池模板: 四虎紧急自动转跳在线视频 | 国产拍揄自揄免费观看 | 欧美日韩另类视频偷拍 | 欧美日韩高清一区二区 | 另类一区二区三区 | 狠狠欧美| 亚洲国产成人私人影院 | 日本不卡一 | 丁香五月激情婷婷五月天 | 久久无码精品一一区二区三区 | 二区精品在线观看 | 人妻无码中文字幕一区二区三区 | 国产精品后入内射日本在线观看 | 二区三区人 | 久久国产精品亚洲欧美日韩 | 亚洲av无码国产剧情 | 国产色精品久久人妻无码看 | 久久综合给合久久97色美利坚 | 熟女人妻精品一区二区三 | 亚洲午夜久久久精品影院 | 国产成人精品视频一区二区三区 | 99久久九九国产精品国产 | 国产精品高潮呻吟久久vr乱吗 | 精品国产伦一区二区三区在线观看 | 欧美黄网站色视频免费 | 精品国产片自在线拍免费看 | 精品无码一区二区河北彩花 | 91Tims| 国产精品原创尤物菠萝蜜 | 国产亚洲欧美日韩久久图片 | 91精品国产一区二区 | 国产精品免费aⅴ片在线观看 | 国产三级多多影院 | 国产无遮挡A片无码免费 | 国产精品福利自产拍在线观看 | a级欧美黄片免费观看 | 国产a精品一区二区三区不 国产a精品一区二区三区不卡 | 亚洲国产日本情侣小视频 | 国产人妻人伦精品熟女麻豆 | 国产免费A片在线观看人 | 午夜无码毛片AV久久 |